Editorial. Examines the use of recombinant human isulin growth factor-1 for uremic hyperleptinemia. Characterization of leptin metabolism in end-stage renal disease (ESRD); Occurrence of receptor-mediated disposal in nonrenal tissues; Mechanisms of hyperleptinemic in ESRD patients.